Tesamorelin 5 mg
Main Image

Tesamorelin 5 mg

Steroids British Dragon Pharmaceuticals British

$42.00

British Dragon Tesamorelin 5 mg – Potent GHRH Analog

✔ High-purity lyophilized powder ✔ 5 mg per 2 mL vial ✔ Potent GHRH (1-44) analog ✔ USA & International shipping

British Dragon Tesamorelin 5 mg is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically the full-length GHRH (1-44) sequence with a chemical modification that enhances its resistance to enzymatic degradation. Each 2 mL vial contains 5 mg of lyophilized Tesamorelin, designed for reconstitution in research settings investigating metabolic function, body composition, and growth hormone regulation.

Tesamorelin acts on the pituitary somatotrophs to stimulate endogenous growth hormone release with greater potency and duration than shorter GHRH analogs. For researchers studying visceral adiposity and metabolic parameters, this peptide offers distinct advantages. Explore similar research compounds like Sermorelin 5 mg or Ipamorelin 5 mg.

What Makes British Dragon Tesamorelin Unique?

Tesamorelin contains a trans-3-hexenoic acid modification at the N-terminus, which confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, resulting in a longer half-life compared to unmodified GHRH (1-44). This modification allows for once-daily administration in research protocols while maintaining biological activity.

For metabolic research, Tesamorelin has been extensively studied for its effects on visceral adipose tissue and metabolic parameters. The 5 mg dosage provides sufficient material for extended research protocols investigating chronic GHRH analog administration. Researchers may also compare Tesamorelin with Sermorelin to evaluate differences between GHRH fragments and full-length analogs.

Benefits of British Dragon Tesamorelin for Research

  • ✔ Full-length GHRH (1-44) analog with enhanced stability
  • ✔ DPP-4 resistant for extended duration of action
  • ✔ 5 mg lyophilized powder for reconstitution flexibility
  • ✔ Suitable for subcutaneous administration research
  • ✔ Relevant for metabolic and body composition studies
Research Grade

British Dragon Tesamorelin 5 mg is intended for laboratory research only. Not for human consumption or clinical use.

External research on Tesamorelin's mechanisms can be explored via PubMed for peer-reviewed studies.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:
Brand: British Dragon Pharmaceuticals
Manufacturer: British Dragon Pharmaceuticals
Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage &amp; Usage Guidelines for Research</h2> <div class="info-card warning"> <p><strong>For laboratory research use only.</strong> Not for human consumption. Reconstitution and handling must be performed by qualified personnel using sterile techniques.</p> </div> <h3>Reconstitution Protocol</h3> <ul class="usage-highlights"> <li>✔ Add 2-3 mL bacteriostatic water to the 5 mg vial</li> <li>✔ Swirl gently; do not shake</li> <li>✔ Store reconstituted peptide at 2-8°C and use within 30 days</li> </ul> <p>The standard reconstitution yields a concentration of approximately 1.67-2.5 mg/mL (1670-2500 mcg/mL). For precise dosing, researchers should calculate based on desired mg per injection volume.</p> <h3>Typical Research Parameters</h3> <p>In animal models, Tesamorelin is often administered at dosages ranging from 1-2 mg per day. Due to its approximately 2-hour half-life, once-daily administration is typical in prolonged studies. Subcutaneous injection is the standard route for systemic absorption research.</p> <ul> <li>✔ Subcutaneous injection: 1-2 mg once daily</li> <li>✔ Research models: Dosing typically scaled by body weight</li> <li>✔ Study duration: 4-12 weeks for metabolic and body composition studies</li> </ul> <h3>Combination Research</h3> <p>Tesamorelin is often studied in isolation for its effects on GH release and metabolic parameters. However, some protocols combine it with GHRP compounds to evaluate synergistic effects on GH pulsatility. For comprehensive metabolic research, explore our range of <a href="/british-dragon-2079/mots-c-10-mg-90943">MOTS-c 10 mg</a>.</p> <div class="info-card"> <p><strong>Note:</strong> Dosages mentioned are for research purposes only. Individual response varies in animal models. Always follow institutional animal care guidelines when conducting in vivo research.</p> </div> <h3>What to Avoid During Research</h3> <ul> <li>❌ Do not use if the lyophilized cake appears discolored or collapsed</li> <li>❌ Avoid exposure to high heat or direct light</li> <li>❌ Do not mix with strong solvents or extreme pH solutions</li> <li>❌ Avoid repeated freeze-thaw cycles after reconstitution</li> </ul> </section> </div>
Reviews:
(0 customer reviews)

Technical Details

Peptide Type
Stabilized GHRH Analogue
Peptide Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
Peptide Length
44 Amino-Acid Residues
Parent Peptide
Human Growth Hormone-Releasing Hormone (GHRH)
Structural Modification
N-Terminal trans-3-Hexenoyl Group
Molecular Formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight
5136 g/mol
CAS Number
218949-48-5
PubChem CID
16137828
Receptor Target
GHRH Receptor (GHRHR)
Signaling Pathway
GHRHR / Growth Hormone Axis

Chat on WhatsApp